Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Genentech invests $450 million in Oceanside campus, creating 150 local jobs

By Brian Buntz | February 10, 2023

GenentechGenentech has announced the construction of a new biologics manufacturing facility in Oceanside, California. The facility, located about 35 miles north of San Diego, will use digital technologies to make the production of medicines more efficient and environmentally friendly.

The company hails the plant as one of the world’s most advanced commercial-scale biologics manufacturing facilities.

When operational in 2025, the plant’s modular design will allow for the simultaneous production of multiple medicines. It will also support pivoting quickly from producing one drug to another.

The facility will be the first in the company’s network specifically designed to commercialize biologics for narrower patient populations, including rare diseases and personalized medicines.

Close to talent

Genentech selected the Oceanside campus for its proximity to biotech talent and its clinical supply center in South San Francisco.

Genentech, a division of Roche, has invested approximately $450 million in the Oceanside campus. The investment will add approximately 150 local jobs and reduce the time to transfer production between facilities from 6 to 18 months to just a few days.

In August 2022, Genentech opened a new Clinical Supply Center in South San Francisco.

Designed for efficiency

Genentech designed the facility, which cost $250 million to construct, with the goal of getting products to patients faster and more sustainably.

The South San Francisco plant focuses on producing personalized medicines for small patient groups. It is also designed to be environmentally friendly, with LEED Gold certification and the use of 100% renewable energy.

Like the Oceanside plant, the facility was also designed with a modular design that allows for quick pivoting from one medicine to another. A “copy-paste” strategy that allows for rapid transfer from clinical to commercial production, said Jeff Davis, the executive director of the Clinical Supply Center (CSC), in an interview with Drug Discovery & Development last year. That center also was designed to minimize waste, with efforts to reuse, recycle or recapture energy from plastics used in production. In addition, the location in South San Francisco allows for proximity between R&D and manufacturing operations based in the company’s original home city.

 

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

This is a screenshot from a Varda Space Industries promotional video showing a space capsule with the company's logo docking onto a satellite.
Varda raises $187M Series C for drug manufacturing in space
This is the logo of Hikma.
Hikma to spend another $1B on US manufacturing, R&D
Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE